Table 1.
Clinical variables of non-ST-segment elevation acute coronary syndrome patients with and without MACE at 36-month followup.
| Variable | MACE | P value | |
|---|---|---|---|
| Yes (n = 45) |
No (n = 210) |
||
| Age (years) | 68 ± 11 | 66 ± 11 | 0.24 |
| Men | 25 (55.6%) | 138 (65.7%) | 0.23 |
| Hypertension (>140/90 mmHg) | 32 (71.1%) | 133 (63.3%) | 0.39 |
| Hypercholesterolemia (>5.17 mmol/L) | 19 (42.2%) | 99 (47.1%) | 0.62 |
| Smokers | 31 (68.9%) | 121 (57.6%) | 0.18 |
| Diabetes | 14 (31.1%) | 75 (35.7%) | 0.61 |
| TIMI risk score | 0.47 | ||
| 2 | 9 (20%) | 35 (16.7%) | |
| 3 | 9 (20%) | 74 (35.2%) | |
| 4 | 16 (35.6%) | 58 (27.6%) | |
| 5 | 10 (22.2%) | 38 (18.1%) | |
| 6 | 1 (2.2%) | 5 (2.4%) | |
| Coronary artery disease | 0.35 | ||
| 1 vessel | 22 (4.9%) | 115 (54.8%) | |
| 2 vessel | 13 (28.9%) | 40 (19%) | |
| 3 vessel | 9 (20%) | 45 (21.4%) | |
| LVEF (%) | 54 ± 10 | 56 ± 12 | 0.22 |
| Treatment at admission | |||
| Aspirin | 45 (100%) | 207 (98.6%) | 0.9 |
| Clopidogrel | 39 (86.7%) | 161 (76.7%) | 0.16 |
| Nitrates | 44 (97.8%) | 202 (96.2%) | 0.9 |
| Statins | 45 (100%) | 207 (98.6%) | 0.9 |
| Angiotensin-converting enzyme inhibitors | 18 (40%) | 68 (32.4%) | 0.9 |
| β-Blockers | 42 (93.3%) | 191 (91%) | 0.77 |
| Biochemistry | |||
| Creatinine (mg/dL) | 1.17 ± 0.25 | 1 ± 0.87 | 0.25 |
| Total cholesterol (mmol/L) | 4.05 ± 1.04 | 4.00 ± 1.18 | 0.48 |
| Peak troponin I (ng/mL) | 4.85 ± 0.16 | 4.39 ± 0.17 | 0.09 |
Data is expressed as mean ± standard deviation and number of patients (%) for categorical variables.
MACE: major adverse cardiovascular events; LVEF: left ventricular ejection fraction.